James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Raber, M. N., J. Faintuch, J. L. Abbruzzese, C. Sumrall, and P. Frost. “Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.” Ann Oncol 2, no. 7 (July 1991): 519–20. https://doi.org/10.1093/oxfordjournals.annonc.a058007.

PMID
1911461
Full Text

Abbruzzese, J. L., R. Grunewald, E. A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, and M. N. Raber. “A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.” J Clin Oncol 9, no. 3 (March 1991): 491–98. https://doi.org/10.1200/JCO.1991.9.3.491.

PMID
1999720
Full Text

Grunewald, R., J. L. Abbruzzese, P. Tarassoff, and W. Plunkett. “Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.” Cancer Chemother Pharmacol 27, no. 4 (1991): 258–62. https://doi.org/10.1007/bf00685109.

PMID
1998982
Full Text

Pazdur, R., J. A. Ajani, Y. Z. Patt, R. Winn, D. Jackson, B. Shepard, R. DuBrow, L. Campos, M. Quaraishi, and J. Faintuch. “Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.” J Clin Oncol 8, no. 12 (December 1990): 2027–31. https://doi.org/10.1200/JCO.1990.8.12.2027.

PMID
2230894
Full Text

Grunewald, R., H. Kantarjian, M. J. Keating, J. Abbruzzese, P. Tarassoff, and W. Plunkett. “Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.” Cancer Res 50, no. 21 (November 1, 1990): 6823–26.

PMID
2208147
Scholars@Duke

Abbruzzese, J. L., B. Levin, J. A. Ajani, J. S. Faintuch, R. Pazdur, S. Saks, C. Edwards, and J. U. Gutterman. “A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.” J Biol Response Mod 9, no. 5 (October 1990): 522–27.

PMID
2123922
Scholars@Duke

Frost, P., J. L. Abbruzzese, B. Hunt, D. Lee, and M. Ellis. “Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.” Cancer Res 50, no. 15 (August 1, 1990): 4572–77.

PMID
1695122
Scholars@Duke

Ajani, J. A., J. A. Roth, B. Ryan, M. McMurtrey, T. A. Rich, D. E. Jackson, J. L. Abbruzzese, B. Levin, L. DeCaro, and C. Mountain. “Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 8, no. 7 (July 1990): 1231–38. https://doi.org/10.1200/jco.1990.8.7.1231.

PMID
2358838
Full Text

Ajani, J. A., J. L. Abbruzzese, J. S. Faintuch, Y. Z. Patt, B. M. Boman, D. E. Jackson, B. Levin, and I. H. Krakoff. “A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.” Cancer Invest 8, no. 6 (1990): 619–21. https://doi.org/10.3109/07357909009018929.

PMID
2149834
Full Text

Abbruzzese, J. L., R. Amato, S. Schmidt, M. N. Raber, and P. Frost. “Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.” Cancer Chemother Pharmacol 26, no. 3 (1990): 159–62. https://doi.org/10.1007/bf02897192.

PMID
2357761
Full Text

Pages